4. Tropical Infections (Malaria, Dengue, Leptospirosis, Scrub Typhus)

Quick Recap

Infectious Diseases System, Protocol 4/6. Covers the major severe tropical/vector-borne infections requiring ICU-level care: severe malaria, dengue hemorrhagic fever/shock syndrome, leptospirosis (Weil's disease), and scrub typhus.

1. General Approach

All four entities share a common clinical trap: early presentation is often nonspecific (fever, myalgia, headache), easily mistaken for a routine viral illness — the diagnosis is frequently made only once warning signs or organ dysfunction develop. Travel/residence history, seasonal/geographic context, and exposure history (mosquito bites, freshwater/flood water contact, rodent exposure, rural/forested activity) are essential and easily overlooked in a busy ICU workup, especially in non-endemic settings receiving a returning traveler. Co-infection (e.g., malaria + typhoid, dengue + leptospirosis) is well recognized in endemic settings and should be considered when the clinical picture is atypical or the patient fails to improve on single-pathogen-directed therapy.

2. Severe Malaria

Causative organism: Plasmodium falciparum causes the vast majority of severe/life-threatening malaria; P. vivax and P. knowlesi can also cause severe disease less commonly.

WHO criteria for severe malaria (any ONE feature, in the presence of P. falciparum parasitemia, defines severe disease):

• Impaired consciousness (GCS <11) or cerebral malaria (unarousable coma not attributable to another cause)
• Prostration (inability to sit/stand/drink without assistance)
• Multiple convulsions (>2 in 24h)
• Acidosis (bicarbonate <15 mmol/L or lactate >5 mmol/L)
• Hypoglycemia (<40 mg/dL) — both disease- and quinine-treatment-related
• Severe malarial anemia (Hb <7 g/dL with parasitemia >10,000/uL)
• Renal impairment (creatinine >3 mg/dL or urea >20 mmol/L)
• Jaundice (bilirubin >3 mg/dL) plus parasitemia >100,000/uL
• Pulmonary edema/ARDS
• Significant bleeding/DIC
• Shock (compensated or decompensated, "algid malaria")
• Hyperparasitemia (>10% parasitized RBCs, or >2% in non-immune individuals)

Immediate stabilization/treatment:

• IV artesunate is the treatment of choice for severe malaria (superior to quinine in RCT evidence, reduced mortality) — 2.4 mg/kg IV at 0, 12, 24h, then daily, with transition to a full oral ACT (artemisinin-based combination therapy) course once the patient can tolerate oral intake and has completed at least 24h of parenteral therapy
• IV quinine as an alternative if artesunate is unavailable — requires cardiac monitoring (QT prolongation) and close glucose monitoring (quinine-induced hyperinsulinemic hypoglycemia)
• Correct hypoglycemia aggressively and monitor frequently, especially in cerebral malaria and with quinine use
• Exchange transfusion has been used historically for extreme hyperparasitemia but evidence for benefit is weak/not clearly established — not routinely recommended
• Avoid corticosteroids in cerebral malaria — shown to worsen outcomes in trials, unlike some other cerebral edema contexts
• Treat seizures per Status Epilepticus protocol; manage ARDS/pulmonary edema with lung-protective ventilation per the ARDS protocol; renal support (CRRT preferred for hemodynamic tolerance) per AKI/CRRT protocols if renal failure develops

Parasitemia should be monitored serially (smear or PCR) to confirm treatment response; failure to clear or rising parasitemia despite therapy should prompt reassessment for resistance or an alternative/co-existing diagnosis.

3. Dengue — Warning Signs, DHF, and Dengue Shock Syndrome

Classification (WHO 2009): dengue without warning signs; dengue with warning signs (abdominal pain/tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy/restlessness, liver enlargement >2cm, rising hematocrit with concurrently falling platelets); severe dengue (severe plasma leakage leading to shock or fluid accumulation with respiratory distress, severe bleeding, or severe organ impairment).

Critical period: typically occurs around defervescence (as fever breaks, day 3-7 of illness) — this is when plasma leakage and shock risk are highest, and paradoxically often when families/patients feel the illness is resolving — close monitoring through this window is essential even as the patient appears to be improving symptomatically.

Dengue Shock Syndrome (DSS): results from significant plasma leakage (capillary permeability increase) causing hypovolemic shock — narrow pulse pressure (<=20 mmHg) is often an EARLY sign, preceding overt hypotension.

Management principles:

• Careful, judicious fluid management is the cornerstone — both under- and over-resuscitation carry real risk; use isotonic crystalloid, titrated to hematocrit trend, urine output, and clinical perfusion, with FREQUENT reassessment given the rapidly evolving plasma leak/reabsorption phases
• Avoid NSAIDs and aspirin (bleeding risk, given the thrombocytopenia and coagulopathy potential) — use acetaminophen for fever/pain control
• Platelet transfusion is NOT routinely recommended for thrombocytopenia alone absent significant active bleeding — prophylactic platelet transfusion has not shown benefit in trials and does not prevent bleeding in dengue specifically
• Monitor hematocrit trend closely — a RISING hematocrit reflects ongoing plasma leakage/hemoconcentration (worsening), while a FALLING hematocrit in the setting of clinical deterioration may indicate significant hemorrhage rather than improvement — interpret hematocrit trend in the context of the overall clinical picture, not in isolation
• Recognize the triphasic course: febrile phase -> critical phase (plasma leakage/shock risk, typically 24-48h) -> recovery/reabsorption phase (fluid reabsorption from the extravascular space back into circulation, risking volume overload if aggressive fluids from the critical phase are not appropriately weaned)
• Blood product transfusion (PRBC) for significant hemorrhage; avoid over-transfusion once bleeding is controlled given reabsorption-phase volume overload risk

4. Leptospirosis (Weil's Disease)

Exposure history: freshwater contact (flooding, rice paddies, contaminated water), rodent exposure, occupational risk (farmers, sewage workers, veterinarians) — actively elicit this history, as leptospirosis is easily missed without it.

Severe presentation (Weil's disease): jaundice, acute kidney injury, hemorrhage (pulmonary hemorrhage is a particularly feared, high-mortality complication), and variable degrees of hepatic dysfunction — the classic triad of jaundice + AKI + hemorrhage should prompt strong consideration.

Pulmonary hemorrhage syndrome: a severe, potentially rapidly fatal complication with diffuse alveolar hemorrhage — manage per general principles in the Diffuse Alveolar Hemorrhage protocol (Respiratory System) for the respiratory support component, while directing leptospirosis-specific antimicrobial therapy.

Diagnosis: clinical suspicion + exposure history is often the primary driver of empiric treatment initiation, given that confirmatory serology (MAT, ELISA) or PCR often has delayed turnaround — do not withhold empiric antibiotic therapy pending confirmatory testing in a compatible clinical picture with significant exposure history.

Treatment:

• Severe disease: IV penicillin G, or IV ceftriaxone/cefotaxime as alternatives (equally effective per trial data, with ceftriaxone offering once-daily dosing convenience)
• Mild-moderate disease: oral doxycycline
• Jarisch-Herxheimer-like reaction can occur after antibiotic initiation (fever, worsening symptoms from rapid organism lysis) — monitor closely in the first hours after starting therapy, though this should not deter treatment initiation

Supportive care: aggressive fluid/renal support (leptospirosis-associated AKI is often non-oliguric and may respond well to supportive management; RRT per standard AKI/CRRT protocol indications if needed), respiratory support for pulmonary hemorrhage, blood product support for significant bleeding/thrombocytopenia.

5. Scrub Typhus

Causative organism: Orientia tsutsugamushi, transmitted by chigger mite bites, endemic to the "tsutsugamushi triangle" (South/Southeast Asia, northern Australia, and the western Pacific).

Classic finding: an ESCHAR at the bite site (a painless, black, necrotic ulcer with surrounding erythema) — highly specific when present but frequently ABSENT or missed on exam (located in skin folds, groin, axilla — actively and thoroughly search these areas in any compatible febrile illness from an endemic region) — its absence does NOT exclude the diagnosis.

Presentation: fever, headache, myalgia, lymphadenopathy, maculopapular rash; can progress to multi-organ dysfunction — pneumonitis/ARDS, myocarditis, meningoencephalitis, hepatic dysfunction, AKI, and shock in severe cases.

Treatment:

• Doxycycline is first-line, including in severe/ICU-level disease — typically shows rapid clinical response (defervescence within 48h) when correctly diagnosed and treated, which can itself serve as a retrospective diagnostic confirmation ("therapeutic trial") in a compatible clinical picture with an inconclusive initial workup
• Azithromycin as an alternative, notably preferred in pregnancy (doxycycline relatively contraindicated) and in some doxycycline-resistant regions (parts of Southeast Asia have reported reduced doxycycline responsiveness)
• Do not withhold empiric doxycycline while awaiting serologic confirmation (IFA/ELISA) in a compatible clinical and epidemiologic picture — delayed treatment is associated with worse outcomes, and the treatment itself is low-risk

6. Immediate Stabilization (ABCDE) — Shared Principles

Airway/Breathing: support per standard indications; ARDS/pulmonary involvement is a shared complication across malaria, dengue, leptospirosis, and scrub typhus — apply lung-protective ventilation per the ARDS protocol regardless of the specific tropical pathogen.

Circulation: shock in these conditions can be hypovolemic (dengue plasma leakage, hemorrhage), septic/distributive (any of the four with severe systemic infection), or a mixed picture — use POCUS-guided assessment per the Undifferentiated Shock framework rather than assuming a single mechanism.

Checklist:

7. Organ Support

Lung-protective ventilation for ARDS/pulmonary hemorrhage; careful fluid resuscitation (especially critical/nuanced in dengue); CRRT for AKI (preferred for hemodynamic tolerance); blood product support for hemorrhage/severe thrombocytopenia (with the dengue-specific caution against routine prophylactic platelet transfusion); standard ICU supportive care.

8. Consultation Matrix

9. Monitoring Framework

Serial parasitemia (malaria), serial hematocrit/platelet trend with clinical correlation (dengue, interpreted per Section 3's nuance), renal/hepatic function trend, respiratory status, neurologic status (cerebral malaria, scrub typhus/leptospirosis CNS involvement), temperature response to therapy (scrub typhus/leptospirosis treatment response marker).

10. Complications

Cerebral malaria/coma, ARDS, AKI, DIC/severe hemorrhage (especially leptospirosis pulmonary hemorrhage and dengue hemorrhagic manifestations), dengue shock syndrome, myocarditis (scrub typhus, leptospirosis), volume overload during the dengue reabsorption phase if fluids not appropriately weaned. Prevention: prompt pathogen-specific empiric therapy without diagnostic delay, careful phase-appropriate fluid management in dengue, thorough eschar search in suspected scrub typhus. Rescue: standard organ-support protocols (ARDS, AKI/CRRT, shock management) applied to the specific tropical infection context.

11. Escalation & De-escalation

Escalate: WHO severe malaria criteria met -> IV artesunate + ICU admission; dengue warning signs progressing to shock -> aggressive judicious fluid resuscitation, ICU-level monitoring; leptospirosis/scrub typhus with organ dysfunction -> ICU admission with organ-specific support.

De-escalate: parasitemia clearing and clinical improvement (malaria) -> transition to oral ACT; dengue past the critical period into recovery/reabsorption phase -> wean fluids proactively to avoid overload; defervescence and clinical improvement on doxycycline (scrub typhus/leptospirosis) -> complete oral course, transition to ward-level care.

12. ICU Discharge Criteria

Hemodynamically stable, organ dysfunction stabilized/improving, parasitemia clearing (malaria) or past the critical/reabsorption phase (dengue), afebrile trend on appropriate antimicrobial therapy (leptospirosis/scrub typhus), no ongoing hemorrhage.

13. Documentation & Medicolegal Checklist

14. Key Guidelines

World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO; 2015 (or current edition). World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control, 2009 (or current WHO SEARO revised guidelines).

15. Controversies

Exchange transfusion for extreme hyperparasitemia in severe malaria lacks strong evidence and is not routinely recommended despite historical use. Optimal fluid resuscitation strategy/targets in dengue shock syndrome remain an area of ongoing study given the narrow therapeutic window between under- and over-resuscitation across the triphasic disease course. Doxycycline resistance/reduced responsiveness in scrub typhus in parts of Southeast Asia is an evolving epidemiologic concern affecting first-line therapy choice in specific regions.

16. References

1. World Health Organization. Guidelines for the treatment of malaria, 3rd ed. WHO; 2015.
2. Dondorp AM, Nosten F, Yi P, et al. Artesunate versus quinine in the treatment of severe falciparum malaria (SEAQUAMAT trial). Lancet. 2005;366(9487):717-725.
3. World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. WHO/TDR; 2009.
4. Costa F, Hagan JE, Calcagno J, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):e0003898.
5. Taylor AJ, Paris DH, Newton PN. A systematic review of mortality from untreated scrub typhus. PLoS Negl Trop Dis. 2015;9(8):e0003971.
6. Chawla R, Todi S, eds. Severe Tropical Infections: Malaria, Typhoid, Scrub Typhus and Zoonosis. ICU Protocols: A Step-wise Approach, 2nd ed. Springer; 2020.

See also: ARDS, Diffuse Alveolar Hemorrhage (Respiratory System) and Acute Kidney Injury, CRRT Indications (Renal System) for the organ-support protocols these tropical infections commonly require.